Bristol-Myers Value Stock - Dividend - Research Selection
Bristol-Myers
ISIN: US1101221083, WKN: 850501
Market price: 76,22 USD
Bristol-Myers Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 10-02-2022 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 16.207.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -973.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | 15.233.999.872 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 36.006.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 109.314.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | 6.994.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | 3,120 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 2.245.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 46.385.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | BMY |
| Market Capitalization | 171.113.906.176,00 USD |
| Country | United States |
| Indices | MSCI World Index,S&P 500 |
| Sectors | Pharmaceuticals |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | 2001-08-07,1000000.0000/951777.0000; 1999-03-01,2.0000/1.0000; 1997-03-03,2.0000/1.0000; 1987-06-10,2.0000/1.0000; 1983-05-27,2.0000/1.0000; 1977-05-31,2.0000/1.0000 |
| Internet | www.bms.com |
Description of the company
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.